Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for KalVista Pharmaceuticals (KALV), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
-8.28
P/B ratioShare price divided by book value per share.
0.00
P/S ratioMarket value divided by annual revenue.
12.30
PEG ratioP/E divided by the earnings growth rate.
-79.28
EV / RevenueEnterprise value against annual revenue.
12.77
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-12.08%
Free cash flow yieldFree cash flow as a percentage of market value.
-1.67%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
92.03%
Operating marginRevenue left after operating costs.
-1.21%
Net marginRevenue left after every cost, including tax and interest.
-1.19%
Return on equityProfit as a percentage of shareholders’ equity.
5466.67%
Return on assetsProfit as a percentage of total assets.
-48.96%
Return on capital employedOperating profit against the capital the business uses.
5733.33%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
5.58
Quick ratioThe same, excluding inventory.
5.52
Cash ratioCash alone against current liabilities.
4.02
Debt to equityTotal borrowings against shareholders’ equity.
-104.83
Debt to assetsTotal borrowings against total assets.
0.45
Interest coverageHow many times operating profit covers the interest bill.
-9.05
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
$-3.23
Shares outstandingShares currently issued.
0
Market capitalisationShare price times shares outstanding.
$1.44B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$1.35B
EmployeesReported headcount.
150
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
KalVista Pharmaceuticals (KALV) trades on a price-to-earnings ratio of -8.28. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.
What is KalVista Pharmaceuticals's return on equity?
KalVista Pharmaceuticals (KALV) reports a return on equity of 5466.67%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does KalVista Pharmaceuticals carry?
KalVista Pharmaceuticals (KALV) has a debt-to-equity ratio of -104.83, which compares total borrowings with shareholders' equity.
What is KalVista Pharmaceuticals's profit margin?
KalVista Pharmaceuticals (KALV) keeps -1.19% of revenue as net profit after every cost, including tax and interest.